Invasive amoebiasis: A review of *Entamoeba* infections highlighted with case reports

Christopher Skappak PhD1, Sarah Akierman BSc BA2, Sara Belga MD3, Kerri Novak MD FRCP1,4, Kris Chadee PhD1, Stefan J Urbanski MD FRCP3, Deirdre Church MD PhD FRCP1, Paul I Beck PhD MD FRCP1,4

©2014 Pulsus Group Inc. All rights reserved

**Methods**

The Calgary Zone, Alberta Health Services (CZ-AHS) serves a population of 1.2 million residents of Calgary and surrounding communities. All laboratory and pathology services for CZ-AHS are centralized and have searchable databases. The pathology database was searched for all reports containing the words “Entamoeba histolytica,” “Entamoeba” and “E. histolytica,” from 2001 to 2011. The microbiology database was searched for all positive stool studies consistent with *Entamoeba*. The microbiology database was searched from 2006 to 2011 for all positive stool ova and parasite (O&P) microscopic examinations that reported the presence of *Entamoeba*; data were only available from this period of time. Age (2007 to 2011) and sex (2006 to 2011), however, were the only variables that could be assessed due to privacy and ethics regulations. Unfortunately, *E. histolytica* cannot be morphologically differentiated from *Entamoeba dispar* (a common non-invasive parasite) and *Entamoeba moshkovskii* (considered primarily to be a free-living amoeba); however, *E. dispar* and *E. moshkovskii* are generally believed to be nonpathogenic. Commercial ELISAs and molecular biological testing, such as polymerase chain reaction (PCR), are available to differentiate *E. histolytica* from *E. dispar* but they are not routinely used in the CZ-AHS due to the rarity of these infections in the region. *Entamoeba* serology testing can diagnose infection with *E. histolytica* (both *E. dispar* and *E. moshkovskii* do not elicit an antibody response), although it also is not routinely ordered because it takes up to 12 weeks before results are available from the reference laboratory. Serology test results for most of the patients were, therefore, not available. No commercial molecular methods are currently available for distinguishing *E. moshkovskii*, although PCR has been used to detect this parasite directly in stool samples during surveillance studies (4). Because serology testing is sent to a reference laboratory, these data were not searchable.

The CZ-AHS pathology database was searched from 2001 to 2011 to identify all cases of invasive *E. histolytica*. Data are presented as mean ± SEM. Statistical analysis was performed using GraphPad Prism (GraphPad, USA) using a parametric unpaired t test for age and nonparametric Mann-Whitney for sex. Ethics approval was obtained from the CZ-AHS for a limited data recovery as above. Permission to present these data was obtained from both individuals.

**Results**

Data were available for stool O&P analysis in the CZ-AHS from January 2006 to December 31, 2011. From 2006 to 2011, a mean (± SEM) of 63.7 ± 2.3 cases of *Entamoeba* were diagnosed according to stool O&P
examination (Figure 1A). Again, this would include *E histolytica*, *E dispar* and *E moshkovskii*. During the time period assessed, *Entamoeba* was more commonly diagnosed in men (39.0±2.4 cases/year) versus women (24.7±3.4 cases/year) (P<0.01). The average age of diagnosis was 31.7 years, with men being slightly older (33.2 years) than females (30.1 years) (P=0.25 [not significant]) (Figure 1B).

The CZ-AHS pathology database search from 2001 to 2011 revealed a total of seven cases, with three females and a mean age of 55±7.4 years (this includes the two cases reported below). In six cases, colitis with invasive *E histolytica* was only noted in the cecum and ascending colon and, in one case (patient 1 below), there was evidence of *E histolytica* throughout the colon involving the rectum to the cecum. Again, no further details of these cases could be obtained except for the two cases described below.

**Patient 1**

A 56-year-old heterosexual man presented to the emergency department with a 10-day history of abdominal pain, nausea and vomiting, and diarrhea. The patient denied taking any medication and had no history of recent travel. His medical history was also unremarkable and he denied having any previous homosexual partners. On physical examination, the patient had a temperature of 38.4°C, a heart rate of 110 beats/min and a blood pressure of 95/55 mmHg. Head and neck, respiratory and cardiovascular, and musculoskeletal examinations were all normal. The patient had a distended abdomen and identified marked right lower quadrant tenderness with guarding. Laboratory results revealed a hemoglobin level of 127 g/L (normal 127 g/L to 165 g/L), an increased white blood cell count of 18.2×10⁹/L (normal 4.0×10⁹/L to 11.0×10⁹/L), lactate level of 8.2 mmol/L (normal 0.5 mmol/L to 2.2 mmol/L) and increased levels of alkaline phosphatase (232 U/L [normal 30 U/L to 145 U/L]) and gamma glutamyl-transferase (176 U/L [normal 11 U/L to 63 U/L]).

Computed tomography (CT) imaging of the abdomen and pelvis revealed severe colitis involving the cecum and ascending colon, and liver abscesses (Figures 2A and 2B). The liver abscesses were drained and the fluid was analyzed. Although microscopic examination of the fluid revealed an increased number of neutrophils, no organisms were visualized on Gram stain and the fluid cultures were negative. At this point, the differential diagnosis included infection, ischemia and new-onset inflammatory bowel disease (IBD). Blood and stool cultures, stool testing for O&P and *Clostridium difficile* were all negative. Serology for *Entamoeba* and *Yersinia* were also sent to the reference laboratory. The patient was initially treated with broad-spectrum antibiotics and conservative management.

Despite broad-spectrum antibiotics and conservative management, the patient deteriorated, developing more severe abdominal pain, with guarding and nausea. A repeat CT scan revealed worsening of colitis with increased bowel wall thickening, pericolic stranding and free fluid (Figures 2C and 2D). A colonoscopy was performed and classic amoebic ulcers were visualized (Figures 3A and 3B) and biopsies were collected. Histological examination revealed classic features of *E histolytica* (Figures 4A and 4B). The patient was treated with 14 days of metronidazole (750 mg per oral three times per day) followed by seven days of paromomycin (500 mg per oral three times per day). His symptoms resolved rapidly; however, a colonoscopy performed three months later showed normal colonic mucosa with a mid-transverse colonic stricture. After six weeks, his serology result was available and was positive for *E histolytica* and negative for *Yersinia*. This stricture did not cause symptoms and it has gradually improved over three years of follow-up.

**Patient 2**

A 24-year-old heterosexual man presented to the outpatient gastroenterology clinic with a three-month history of intermittent diarrhea...
and rectal bleeding. He lived in Bulgaria until eight years of age before immigrating to Canada. The patient had returned to Bulgaria for five months approximately one year previously. He was never sick nor did he experience any GI issues during his stay. Approximately four months after his visit to Bulgaria, he developed bloody diarrhea (at most six bowel motions per day) and lost 5.85 kg (13 lbs), which was associated with abdominal pain, bloating and tenesmus. At that time, his hemoglobin level was normal but his platelet count was slightly elevated (408×10^9/L [normal 150×10^9/L to 400×10^9/L]), as was his white blood cell count (11.9×10^9/L [normal 4.0×10^9/L to 11.0×10^9/L]) and erythrocyte sedimentation rate (13 mm [normal 0 mm to 10 mm]). His electrolyte and thyroid stimulating hormone levels, liver function studies, celiac serology, HIV serology and stool studies (O&I, C difficile, C difficle toxin, culture and sensitivities) were all normal. A colonoscopy was performed (Figures 3C and 3D) and biopsies were collected. There were many endoscopic features consistent with Crohn disease including skip segments, deep ulcers and some linear ulcers. The ileum was normal. Biopsies again revealed classic features of E histolytica (Figures 4C and 4D). A CT scan was performed after the diagnosis and revealed colonic inflammation but no liver abscesses (not shown). The patient had a complete and rapid response to a 10-day course of metronidazole (750 mg per oral three times per day) followed by seven days of paromomycin (500 mg per oral three times per day). Serology was not performed.

**DISCUSSION**

Locally acquired E histolytica infections are a very rare occurrence in urban Canada aside from travellers, recent immigrants and the male homosexual population (5). A recent study investigating the prevalence of intestinal parasites in the United States demonstrated that for individuals infected with a single GI parasite, <5% were caused by E histolytica or a similar asymptomatic species (E dispar) (6). In the United States, the annual incidence of amoebic liver abscess (occurring in <1% of E histolytica colitis cases) was 1.38 per million population and mostly occurred in Hispanic men in the western and southern states (7). Similar studies have not been undertaken across Canada; however, E histolytica infections have been reported in both humans and canines in Canadian northern Aboriginal communities (2,8). A recent study from Ontario (9) reported 29 cases of amoebic liver abscesses that presented to seven hospitals in Toronto over a 30-year period. Of these cases, 86% had recent travel to endemic areas and some patients were born in endemic areas (9). They did not report any cases that developed in Canada without recent travel, foreign birth or other risk factors (9). Because most studies from endemic areas report that <1% of individuals with E histolytica colitis develop a liver abscess and only 10% with E histolytica in their stool develop invasive disease, one could estimate that in the Toronto area (based on one E histolytica abscess per year) there are >100 cases of E histolytica colitis per year and approximately 1000 without invasive disease (carriers).

Our two sources of review of the CZ-AHS databases consisted of identifying positive stool studies and intestinal pathology. On average, 63.7 cases of Entamoeba were identified by stool studies per year (Figure 1). As noted above, these are based on light microscopy assessment of morphology and cannot differentiate E histolytica from the nonpathogenic E dispar and E moshkovskii. This is likely an underestimate of the incidence/prevalence of Entamoeba in the CZ-AHS due to the low sensitivity and specificity (discussed further below). In the Ontario study above, only 24% of cases of proven E histolytica were found to have positive stool studies (9). Seven (including our two cases) were identified on review of pathology over a 10-year period.

There are several risk factors for acquiring E histolytica infection other than recent travel to an endemic area, including men who have sex with men (MSM). In a study from Los Angeles (USA), 6% of MSM were seropositive for E histolytica; however, significantly higher rates have been reported in MSM populations in other parts of the world including Rome, Italy (21%), Mexico City, Mexico (25% of HIV-positive MSM) and South Africa (43% in HIV positive and 15% in HIV negative, and 69% in those 50 to 59 years of age) (10,11). Both individuals in our study denied ever engaging in sex with men.

E histolytica is a parasite that is transmissible by the oral-fecal route. Infections can range from asymptomatic to severe or fatal invasions of multiple organ systems. Asymptomatic infections are responsible for

**Figure 3** Colonoscopic imaging of patient 1 (A and B) and patient 2 (C and D) demonstrating classic amoebic ulceration in both patients (arrows).

**Figure 4** A and B Colon biopsies of patient 1. Alcian blue periodic acid Shiff (PAS) stain (A: original magnification ×40, B: higher magnification of A), arrows indicate Entamoeba histolytica trophozoites (many do not have arrows). C and D Patient 2 (hematoxylin and eosin stain C: original magnification ×100, D: higher magnification C, arrows indicate PAS-positive E histolytica trophozoites (many do not have arrows).
the continuous transmission of the parasite because numerous cysts are produced and passed in feces. If exocytosis occurs, *Entamoeba histolytica* trophozoites are produced and invade the intestinal wall leading to amoebic dysentery and resulting in amoebic ulcers (1). Trophozoites are capable of penetrating the intestinal wall and can lead to more severe complications including liver abscesses (the most common) and, in rare cases, can spread to the brain and/or lungs, which is often fatal (12). A typical treatment regimen for *E histolytica* infection is metronidazole for 10 to 14 days (500 mg to 750 mg three times per day) followed by a seven-day treatment of paromomycin (25 mg/kg to 35 mg/kg daily in three divided doses) to eliminate colonization (13).

Amoebic liver abscesses usually present with fever and pain in the right upper quadrant (13,14). Diagnosis of *E histolytica* is based on the patient’s history, imaging modalities, serological findings, stool studies, fecal antigen testing (via ELISA) as well as real-time PCR (9,14). Stool microscopic assessment (which is the most common test used in Canada) has a low sensitivity (10% to 50%) and cannot differentiate *E histolytica* from the noninvasive, nonpathogenic *E dispar* and *E moshkovskii* (both of our cases had negative stool O&P studies) (9,14,15). Typically, a patient’s history reveals recent travel from an endemic area or other risk factors; however, this was not the case in either of our two cases. Serological testing can differentiate *E histolytica* from *E dispar* and *E moshkovskii* (the latter two do not induce antibody responses) (9); the sensitivity and specificity range from 85% to 95% (9-11,15). It is important to differentiate *E histolytica* from *E dispar* because, even in asymptomatic individuals, *E histolytica* should be treated to prevent spread and invasive disease. Unfortunately, most diagnostic laboratories in most centres in Canada refer serological testing to an external site, which can take several weeks before results are available. Stool antigen and DNA tests are generally not available “in house” at most Canadian centres and are discussed further below.

Our first case was unique because it occurred in an individual who was born in Alberta, had not recently travelled to endemic areas and had no other identifiable risk factors. Furthermore, the differential for both cases included IBD. Corticosteroids are contraindicated in both cases included IBD. Corticosteroids are contraindicated in *E histolytica* infection abroad because Eastern Europe has significantly higher prevalence rates than North America (17). As noted above, many individuals who are infected with *E histolytica* are asymptomatic and only approximately 10% develop invasive disease. Thus, although this entire chapter is rare in Canada, one should consider this diagnosis in patients with new symptoms of colitis, especially in those with recent travel to endemic areas.

It can be difficult to differentiate *E histolytica*-associated colitis from IBD and invasive bacterial dysentery. In general, those who present with *E histolytica*-associated colitis have a duration of symptoms >7 days, most will be fecal occult blood positive whereas only approximately 40% of those with invasive bacterial dysentery will be fecal occult positive and generally experience a shorter disease duration (18). Fever (>38°C) is common in invasive bacterial dysentery but is less common in individuals with uncomplicated IBD or *E histolytica*-associated colitis (<40%) (1) (although those with *E histolytica* liver abscesses are commonly febrile) (18). *E histolytica*-associated colitis more commonly presents with weight loss compared with those with invasive bacterial dysentery (18). More than 90% of patients with *E histolytica*-associated colitis present with diarrhea and tenesmus whereas frank blood in stools and fever are rare (18). In short, the history, stool studies and colonic biopsy assessment play critical roles in differentiating *E histolytica*-associated colitis from IBD and invasive bacterial dysentery. Unfortunately, *E histolytica* antigen and antibody tests are not readily available in most North American centres; most laboratories outsource these tests, with results taking seven to 21 days. These ELISA-based antibody tests have a sensitivity and specificity of 85% to 95% but are less useful in patients from endemic areas because they may have antibodies from previous exposure (15). Again, stool studies (microscopy and culture) can miss cases, with studies reporting 10% to 50% sensitivity. Because *E histolytica* trophozoites degenerate rapidly in unfixed fresh samples, fixation and multiple collections increase the yield (18,19). Again, microscopy cannot differentiate *E histolytica* from other *Entamoeba* species. The best tests at present are the PCR- and ELISA-based assays that detect *E histolytica* DNA or antigens in stool, and have sensitivities and specificities of 90% to 95% (18). With the increase in world travel and migration, we may have to consider increasing out use of more rapid and accurate DNA/antigen-based stool studies.

Because *E histolytica*-associated colitis can be localized to the cecum and right colon, a sigmoidoscopy can miss cases (18). Endoscopically, *E histolytica* colitis is associated with mucosal thickening, multiple discrete ulcers separated by regions of normal-appearing mucosa, diffuse inflammation and erythema and, rarely, necrosis and perforation (18). Recently, Upadhyay et al (22) described *E histolytica* ulcers as having a ‘poached egg’ appearance. They describe a patient who had multiple large irregular ulcers with a white slough and yellowish necrotic material on the top of the white slough, giving a ‘poached egg’ appearance. Both of our cases had irregular ulcers with white slough but neither patient had ulcers with the ‘poached egg’ appearance (they were missing the yellowish necrotic material). The most feared complication of *E histolytica*-associated colitis is acute necrotizing colitis and the development of toxic megacolon. This is rare but has been reported in approximately 0.5% of cases and is associated with high mortality (18). *E histolytica* colitis can also rarely be associated with penetrating disease, causing enterocutaneous, rectovaginal and enterovesicular fistulas (18). *E histolytica* can also cause inflammation of the appendix and present as appendicitis; in addition, it can cause pronounced granulomatous inflammation resulting in a pseudotumour that can lead to bowel obstruction (18). Fewer than 1% of individuals with *E histolytica* infections develop extraintestinal features that can include pericarditis, lung abscesses, periitonitis and skin lesions; however, the most common is hepatic abscesses (18). Hepatic abscesses are more common in men (male:female ratio 3.3:1 [23], 7.2:1 [24]), with a peak age of incidence between 30 and 50 years (25), and appears to be associated with increased alcohol consumption (18). Interestingly, a laboratory-based study (26) found that testosterone increased the susceptibility of mice to *E histolytica* liver abscesses by decreasing interferon-gamma secretion by natural killer T cells (26).

**SUMMARY**

With increased travel and emigration, we must keep *E histolytica*-associated colitis in our differential diagnosis list. Because one of our patients had no risk factors for *E histolytica*, we should entertain this diagnosis when we encounter new cases of colitis and wait for biopsies and stool studies before starting corticosteroids for presumed IBD.

**ACKNOWLEDGEMENTS:** Dr Beck is an Alberta Innovates Health Solutions Clinical Scholar and has research grants from Canadian Institute of Health Research and Crohn’s and Colitis Foundation of Canada.

**DISCLOSURES:** The authors have no financial disclosures or conflicts of interest to declare.

**REFERENCES**


Skappak et al
Invasive amoebiasis: A review of *Entamoeba* infections


Gi BodyGuard
This free Smartphone app was developed by the CDHF to maximize physician-patient communication. Patients can now quickly, privately and accurately track bowel patterns, pain, medications, health history, food and exercise. Using this information, Gi BodyGuard creates comprehensive reports and graphs that can be printed or emailed to you so that appointments are more productive.

Gi BodyGuard is now available for iPhone and Android.

New for Kids!
Solving the Mystery of Endoscopy
A fun, interactive, on-line game to help ease anxiety and educate young patients undergoing endoscopy.

WebSeminars for Patients
Developed and hosted by gastroenterologists, these recorded teaching sessions are now available for your patients to view on-line and all the time. Topics currently available include IBS, IBD, GERD, Nutrition and Probiotics with new sessions always being added.

www.CDHF.ca
We are your 24/7 patient resource centre — illustrations, fact sheets, videos, personal stories and more to help you educate your patients effectively and efficiently.

The CDHF is empowering Canadians to take control of their digestive health with confidence and optimism.

Trusted, education materials and expert tools to help you educate your patients.